Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Luye Pharma Group Ltd. (HK:2186)
HKEX:2186
Holding HK:2186?
Track your performance easily
2186 Stock Chart & Stats
Day’s RangeHK$0 - HK$0
52-Week RangeHK$2.34 - HK$4.00
Previous CloseHK$3.02
Volume13.71M
Average Volume (3M)8.72M
Market Cap
HK$11.16B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)13.6
Beta0.94
Next Earnings
Mar 26, 2025EPS Estimate
HK$0.12Last Dividend Ex-Date
Jun 29, 2020Dividend YieldN/A
Share Statistics
EPS (TTM)0.22
Shares OutstandingN/A
10 Day Avg. Volume6,351,000
30 Day Avg. Volume8,720,645
Standard Deviation0.14
R-Squared0.43
Alpha0.00271
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)2.21
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$3.98Price Target Upside31.65% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Luye Pharma Group News
PremiumCompany Announcements
Luye Pharma Group Reports Strong Mid-Year Financials
PremiumCompany Announcements
Luye Pharma Sets Date for Financial Results Review
PremiumCompany Announcements
Luye Pharma Group Completes Key Investment Phase
PremiumCompany Announcements
Luye Pharma’s Breakthrough Drug Enters Clinical TrialsPremiumCompany Announcements
Luye Pharma’s ERZOFRI Wins FDA Approval
PremiumCompany Announcements
Luye Pharma Group Announces Major Investment DealPremiumCompany Announcements
Luye Pharma’s New Pain Drug Approved in China
PremiumCompany Announcements
Luye Pharma’s LY03010 Clears FDA InspectionOptions Prices
Currently, No data available
---
Ownership Overview
33.43%
Insiders
1.99% Mutual Funds
2.16% Other Institutional Investors
62.43% Public Companies and
Individual Investors
2186 FAQ
What was Luye Pharma Group Ltd.’s price range in the past 12 months?
Luye Pharma Group Ltd. lowest stock price was HK$2.34 and its highest was HK$4.00 in the past 12 months.
What is Luye Pharma Group Ltd.’s market cap?
Currently, no data Available
When is Luye Pharma Group Ltd.’s upcoming earnings report date?
Luye Pharma Group Ltd.’s upcoming earnings report date is Mar 26, 2025 which is in 187 days.
How were Luye Pharma Group Ltd.’s earnings last quarter?
Luye Pharma Group Ltd. released its earnings results on Aug 28, 2024. The company reported HK$0.113 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.113.
Is Luye Pharma Group Ltd. overvalued?
According to Wall Street analysts Luye Pharma Group Ltd.’s price is currently Undervalued.
Does Luye Pharma Group Ltd. pay dividends?
Luye Pharma Group Ltd. pays a Annually dividend of HK$0.06 which represents an annual dividend yield of N/A. See more information on Luye Pharma Group Ltd. dividends here
What is Luye Pharma Group Ltd.’s EPS estimate?
Luye Pharma Group Ltd.’s EPS estimate is HK$0.12.
How many shares outstanding does Luye Pharma Group Ltd. have?
Luye Pharma Group Ltd. has 3,761,670,700 shares outstanding.
What happened to Luye Pharma Group Ltd.’s price movement after its last earnings report?
Luye Pharma Group Ltd. reported an EPS of HK$0.113 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.694%.
Which hedge fund is a major shareholder of Luye Pharma Group Ltd.?
Currently, no hedge funds are holding shares in HK:2186
---
Luye Pharma Group Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-8.94%
12-Months-Change
Fundamentals
Return on Equity
6.36%
Trailing 12-Months
Asset Growth
3.39%
Trailing 12-Months
Company Description
Luye Pharma Group Ltd.
Luye Pharma Group Ltd is a major drug manufacturer that focuses on developing, producing, and selling pharmaceutical products. The company's operations are primarily centered in China with treatments focused on oncology, cardiovascular diseases, and metabolism. The vast majority of the company's revenue is generated from oncology drugs, followed by cardiovascular drugs. Luye's growth strategies include continued innovation and globalization while improving its market share in China in the three key therapeutic areas, namely oncology, cardiovascular system and alimentary tract, and metabolism. In addition, Luye intends to strengthen international cooperation while accelerating the launch of product candidates internationally.
---
2186 Stock 12 Month Forecast
Average Price Target
HK$3.98
▲(31.65% Upside)
Technical Analysis
Best Analysts Covering 2186
1 Year
1 Year Success Rate
2/3 ratings generated profit
1 Year Average Return
+36.37%
reiterated a sell rating 6 months ago
Copying Sean Wu CFA's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +36.37% per trade.
---